Haemonetics Debt to Equity Ratio 2010-2025 | HAE
Current and historical debt to equity ratio values for Haemonetics (HAE) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Haemonetics debt/equity for the three months ending March 31, 2025 was 1.12.
| Haemonetics Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2025-03-31 | $1.63B | $0.82B | 1.99 |
| 2024-12-31 | $1.62B | $0.91B | 1.79 |
| 2024-09-30 | $1.65B | $0.88B | 1.87 |
| 2024-06-30 | $1.64B | $0.91B | 1.81 |
| 2024-03-31 | $1.24B | $0.96B | 1.29 |
| 2023-12-31 | $1.26B | $0.94B | 1.33 |
| 2023-09-30 | $1.12B | $0.89B | 1.25 |
| 2023-06-30 | $1.10B | $0.87B | 1.27 |
| 2023-03-31 | $1.12B | $0.82B | 1.37 |
| 2022-12-31 | $1.10B | $0.78B | 1.42 |
| 2022-09-30 | $1.14B | $0.73B | 1.56 |
| 2022-06-30 | $1.05B | $0.77B | 1.36 |
| 2022-03-31 | $1.11B | $0.75B | 1.48 |
| 2021-12-31 | $1.10B | $0.73B | 1.51 |
| 2021-09-30 | $1.10B | $0.70B | 1.58 |
| 2021-06-30 | $1.12B | $0.68B | 1.65 |
| 2021-03-31 | $1.09B | $0.73B | 1.49 |
| 2020-12-31 | $0.60B | $0.72B | 0.83 |
| 2020-09-30 | $0.75B | $0.67B | 1.12 |
| 2020-06-30 | $0.83B | $0.61B | 1.36 |
| 2020-03-31 | $0.68B | $0.59B | 1.16 |
| 2019-12-31 | $0.66B | $0.58B | 1.15 |
| 2019-09-30 | $0.61B | $0.58B | 1.04 |
| 2019-06-30 | $0.67B | $0.59B | 1.13 |
| 2019-03-31 | $0.61B | $0.67B | 0.91 |
| 2018-12-31 | $0.59B | $0.64B | 0.91 |
| 2018-09-30 | $0.56B | $0.70B | 0.81 |
| 2018-06-30 | $0.57B | $0.67B | 0.84 |
| 2018-03-31 | $0.49B | $0.75B | 0.64 |
| 2017-12-31 | $0.49B | $0.82B | 0.59 |
| 2017-09-30 | $0.47B | $0.80B | 0.59 |
| 2017-06-30 | $0.48B | $0.77B | 0.62 |
| 2017-03-31 | $0.50B | $0.74B | 0.68 |
| 2016-12-31 | $0.54B | $0.77B | 0.70 |
| 2016-09-30 | $0.59B | $0.75B | 0.78 |
| 2016-06-30 | $0.60B | $0.72B | 0.84 |
| 2016-03-31 | $0.60B | $0.72B | 0.83 |
| 2015-12-31 | $0.62B | $0.72B | 0.86 |
| 2015-09-30 | $0.64B | $0.78B | 0.83 |
| 2015-06-30 | $0.64B | $0.79B | 0.80 |
| 2015-03-31 | $0.66B | $0.83B | 0.80 |
| 2014-12-31 | $0.64B | $0.83B | 0.77 |
| 2014-09-30 | $0.65B | $0.82B | 0.80 |
| 2014-06-30 | $0.66B | $0.82B | 0.81 |
| 2014-03-31 | $0.68B | $0.84B | 0.81 |
| 2013-12-31 | $0.66B | $0.83B | 0.80 |
| 2013-09-30 | $0.69B | $0.80B | 0.86 |
| 2013-06-30 | $0.71B | $0.77B | 0.91 |
| 2013-03-31 | $0.69B | $0.77B | 0.90 |
| 2012-12-31 | $0.70B | $0.78B | 0.89 |
| 2012-09-30 | $0.68B | $0.77B | 0.88 |
| 2012-06-30 | $0.17B | $0.76B | 0.23 |
| 2012-03-31 | $0.18B | $0.73B | 0.24 |
| 2011-12-31 | $0.14B | $0.71B | 0.20 |
| 2011-09-30 | $0.15B | $0.68B | 0.21 |
| 2011-06-30 | $0.14B | $0.71B | 0.20 |
| 2011-03-31 | $0.15B | $0.69B | 0.21 |
| 2010-12-31 | $0.14B | $0.65B | 0.21 |
| 2010-09-30 | $0.14B | $0.59B | 0.24 |
| 2010-06-30 | $0.13B | $0.57B | 0.24 |
| 2010-03-31 | $0.17B | $0.59B | 0.28 |
| 2009-12-31 | $0.13B | $0.57B | 0.23 |
| 2009-09-30 | $0.14B | $0.58B | 0.23 |
| 2009-06-30 | $0.13B | $0.56B | 0.23 |
| 2009-03-31 | $0.11B | $0.54B | 0.20 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $3.428B | $1.361B |
| Haemonetics Corp. provides blood management solutions to customers encompassing blood and plasma collectors, hospitals and health care providers globally. Its portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood supply chain, helping better clinical outcomes. It acquired Pall Corporation's blood collection, filtration and processing product lines. It entered into a long-term supply agreement with Pall. The company acquired Hemerus Medical. It operates under 3 segments: Plasma, Blood Center, and Hospital. Plasma includes plasma collection devices and disposables, plasma donor management software, anticoagulant and saline sold to plasma customers. Blood Center includes blood collection and processing devices and disposables for red cells, platelets and whole blood as well as related donor management software. Hospital includes three product lines, namely, Hemostasis Management, Cell Salvage and Transfusion Management. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $237.401B | 28.55 |
| Boston Scientific (BSX) | United States | $145.814B | 36.50 |
| Stryker (SYK) | United States | $145.229B | 30.37 |
| EssilorLuxottica (ESLOY) | France | $130.605B | 0.00 |
| Medtronic (MDT) | Ireland | $113.492B | 16.09 |
| Lonza Group Ag (LZAGY) | Switzerland | $51.916B | 0.00 |
| Haleon (HLN) | United Kingdom | $49.556B | 28.23 |
| ResMed (RMD) | United States | $36.981B | 27.78 |
| Agilent Technologies (A) | United States | $33.778B | 22.02 |
| GE HealthCare Technologies (GEHC) | United States | $33.476B | 15.89 |
| Terumo (TRUMY) | Japan | $27.213B | 35.35 |
| Koninklijke Philips (PHG) | Netherlands | $22.201B | 15.96 |
| Insulet (PODD) | United States | $21.367B | 83.87 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.451B | 11.85 |
| Baxter (BAX) | United States | $16.093B | 12.02 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $13.187B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $9.076B | 0.00 |
| Demant (WILYY) | Denmark | $8.854B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.325B | 22.01 |
| Lantheus Holdings (LNTH) | United States | $5.545B | 13.99 |
| Prestige Consumer Healthcare (PBH) | United States | $4.207B | 18.80 |
| Perrigo (PRGO) | Ireland | $3.746B | 9.49 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| ICU Medical (ICUI) | United States | $3.258B | 24.02 |
| Envista Holdings (NVST) | United States | $3.198B | 26.58 |
| GN Store Nord (GNNDY) | Denmark | $2.319B | 19.20 |
| QuidelOrtho (QDEL) | United States | $2.021B | 13.90 |
| LeMaitre Vascular (LMAT) | United States | $1.839B | 41.10 |
| AtriCure (ATRC) | United States | $1.600B | 0.00 |
| Acuren (TIC) | United States | $1.308B | 0.00 |
| Neogen (NEOG) | United States | $1.220B | 15.61 |
| AdaptHealth (AHCO) | United States | $1.187B | 12.05 |
| BioLife Solutions (BLFS) | United States | $1.107B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.061B | 23.86 |
| Phibro Animal Health (PAHC) | United States | $0.993B | 12.70 |
| Kestra Medical Technologies (KMTS) | United States | $0.963B | 0.00 |
| InMode (INMD) | Israel | $0.888B | 8.95 |
| CeriBell (CBLL) | United States | $0.657B | 0.00 |
| Evolus (EOLS) | United States | $0.656B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.637B | 0.00 |
| Owens & Minor (OMI) | United States | $0.616B | 5.11 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.576B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.547B | 0.00 |
| Valneva SE (VALN) | France | $0.523B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.419B | 0.00 |
| Surmodics (SRDX) | United States | $0.416B | 0.00 |
| SNDL (SNDL) | Canada | $0.355B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.351B | 12.92 |
| Aurora Cannabis (ACB) | Canada | $0.342B | 60.90 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.329B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.281B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.268B | 22.60 |
| Sanuwave Health (SNWV) | United States | $0.265B | 0.00 |
| Cerus (CERS) | United States | $0.262B | 0.00 |
| ZimVie (ZIMV) | United States | $0.258B | 11.75 |
| Sanara MedTech (SMTI) | United States | $0.255B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.251B | 0.00 |
| Quanterix (QTRX) | United States | $0.240B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.219B | 0.00 |
| Biote (BTMD) | United States | $0.216B | 6.08 |
| Brainsway (BWAY) | Israel | $0.216B | 57.10 |
| TriSalus Life Sciences (TLSI) | United States | $0.208B | 0.00 |
| Omeros (OMER) | United States | $0.208B | 0.00 |
| Organigram Global (OGI) | Canada | $0.197B | 0.00 |
| High Tide (HITI) | Canada | $0.189B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.186B | 15.18 |
| Verano Holdings (VRNOF) | United States | $0.180B | 0.00 |
| Exagen (XGN) | United States | $0.149B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.143B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.134B | 16.51 |
| Jin Medical (ZJYL) | China | $0.109B | 0.00 |
| MacroGenics (MGNX) | United States | $0.098B | 0.00 |
| Veru (VERU) | United States | $0.096B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.092B | 0.00 |
| Fonar (FONR) | United States | $0.090B | 11.60 |
| Quipt Home Medical (QIPT) | United States | $0.089B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.077B | 0.00 |
| Agape ATP (ATPC) | $0.077B | 0.00 | |
| InterCure (INCR) | Israel | $0.067B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.067B | 0.00 |
| Apyx Medical (APYX) | United States | $0.065B | 0.00 |
| Zynex (ZYXI) | United States | $0.063B | 0.00 |
| ImmuCell (ICCC) | United States | $0.058B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.057B | 0.00 |
| Modular Medical (MODD) | United States | $0.043B | 0.00 |
| Nephros (NEPH) | United States | $0.043B | 57.29 |
| United-Guardian (UG) | United States | $0.038B | 13.02 |
| Rockwell Medical (RMTI) | United States | $0.033B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.020B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.019B | 0.00 |
| Safety Shot (SHOT) | United States | $0.018B | 0.00 |
| Flora Growth (FLGC) | United States | $0.018B | 0.00 |
| INLIF (INLF) | $0.013B | 0.00 | |
| Meihua Medical Technologies (MHUA) | China | $0.012B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.012B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.008B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.006B | 0.00 |
| Senestech (SNES) | United States | $0.005B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |